

Access to innovations in Ukraine



ISPOR Ukraine Regional Chapter
Warsaw 27.03.2019
Oksana Makohonska, PhD, MBA

Patients access to innovations in Ukraine

| Medicines access | | Innovation medicines |
|-----------------------------|----------|--|
| Reimbursement | no | |
| Centralized procurements | yes | |
| NEML | possible | MoH shall take decision based on HTA and negotiation procedure |
| Regional / local purchasing | possible | after 100% covering of essential medicines need |
| Out of pocket | yes | |

Challenges HTA and essential listing in Ukraine

The first step is done: HTA is implemented in Ukraine

| Topic | Difficulties | Solution |
|-------------------------|------------------------|---|
| Professional staff | limited | <ul style="list-style-type: none">- several experts- international consulting- industry knowledge- intention to establish university specialty |
| Protocols | not for all disease | officially foreign and international guidelines can be used |
| Cost of medical service | not publicly available | <ul style="list-style-type: none">- hospital data can be used- unified tariffs in frame of medical guarantees program is under development |
| Final decision taking | HTA is just a part | <ul style="list-style-type: none">- negotiations (MEA, free goods, price confidentiality, payback...) |



SERVIER R&D IS SPECIALIZED ON 5 MAJOR THERAPEUTIC AREAS

- 23 new molecular entities candidates in development
- 50 active Alliances of international partnerships in R&D

OUR RESEARCH FOCUS

CARDIOVASCULAR DISEASES

Pathophysiological & regenerative approaches

DIABETES

Insulin resistance, Inflammation & fibrosis

CANCER

Cancer cell targeting: focus on apoptosis
Immuno-oncology: focus on T-cells

IMMUNE-INFLAMMATORY DISEASES

Cytokine & immune regulatory molecules

NEUROPSYCHIATRIC DISEASES

Proteinopathies

